Results 81 to 90 of about 5,464 (192)

Immediate Spastic Hemiplegia following Coil Embolization of an Anterior Communicating Artery Aneurysm

Case Reports in Neurology, 2011
Background: Acute ischemia typically results in a flaccid paralysis. An immediate spastic hemiparesis following ischemia has rarely been reported.
Jordan Dubow, Lewis Z. Leng, Y.Pierre Gobin   +2 more
doaj   +1 more source

Paradoxical Platelet Activation Was not Observed on Dissociation of Abciximab from GPIIb-IIIa Complexes

, 2002
SummaryThe ability of abciximab to bind and dissociate from platelets raises the question of the conformational state of GPIIb-IIIa complexes losing abciximab and the risk of paradoxical drug-induced platelet activation.
Christel Poujol, Serge Ndoko, Alan Nurden, Paquita Nurden, Robert Combrié   +4 more
core   +1 more source

Vergleich der intrakoronaren zur intravenösen Abciximab-Bolusgabe bei Patienten mit einem akuten Koronarsyndrom

, 2007
In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Clinical trials have studied intravenous administration only.
Schaible, Stefan
core   +1 more source

Terapias emergentes: inhibidores de glicoproteína IIB/IIIA en ataque cerebrovascular agudo

Acta Neurológica Colombiana, 2010
El ataque cerebrovascular (ACV) es una causa común de morbilidad y mortalidad en el mundo. La terapia trom- bolítica con (r-TPA), es la única terapia aprobada para el tratamiento del ACV y esta terapia solo se logra aplicar en el 2 % de los pacientes ...
Juliana Coral Casas
doaj   +2 more sources

Intracoronary reopro during percutaneous coronary intervention in acute and stable patient can influence stent thrombosis formation (IRPASST) study

Heart Views, 2013
Background: In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Most clinical trials have studied mainly intravenous administration.
Mohammed Balghith, Ali Al-Ghamdi, El harif Zain, Ahmed Al-Saileek   +3 more
doaj  

Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions [PDF]

, 2012
Objectives: To perform a systematic review to provide rationale for intracoronary (IC) abciximab administration in patients with ST-segment elevation myocardial infarction (STEMI), to summarize recent studies comparing IC vs.
Goch, Aleksander, Grześk, Grzegorz, Navarese, Eliano Pio, Kubica, Aldona, Kubica, Jacek, Koziński, Marek   +5 more
core  

Switch from abciximab to eptifibatide during percutaneous coronary intervention

, 2009
BACKGROUND: Treatment with glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) reduce ischemic complications and improve outcome.
Grip, Lars,, Odell, Annika,, Tahmasebiepour, Farshad,, Karlsson, Thomas,, Matejka, Göran,, Albertsson, Per,, Wahlin, Magnus,, Wolmeryd, Christina,   +7 more
core  

Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes [PDF]

, 2017
Aims The safety and efficacy of abciximab in addition to low-molecular-weight-heparin as the primary medical treatment of acute coronary syndromes has not previously been investigated.
James, S., Simoons, M.L., Kontny, F., Armstrong, P., Husted, S., Pfisterer, M., Niemminen, M., Wallentin, L., Califf, R.   +8 more
core  

Intrakoronare Gabe von Abciximab bei Patienten mit ST-Hebungsinfarkt

, 2010
Der Glykoprotein IIb/IIIa-Rezeptorantagonist Abciximab (ReoPro®) führte in mehreren randomisierten, placebokontrollierten Studien bei Patienten mit einem akuten Myokardinfarkt zu einer Reduktion der Häufigkeit von schwerwiegenden, unerwünschten kardialen
Shaw, Christine
core   +1 more source

Abciximab readministration: A single-operator community-hospital experience.

, 1999
Abciximab, a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor, reduces ischemic complications of coronary interventions after first administration.
Chang, K S, Arjomand, H, Magsi, Z M, Mascarenhas, D A   +3 more
core